FDAsafety guidance77% confidence
FDA TA — CYCLOPHOSPHAMIDE (ORIG)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Hetero Labs Limited; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA219271. Sponsor: HETERO LABS LIMITED. Submission status: TA. Submission type: ORIG. Review priority: STANDARD. Active ingredients: CYCLOPHOSPHAMIDE.
Supporting Context
- Therapeutic area
- Not specified
- Sub-indication
- General
Related signal: FDA Submission Update for ANDA220866 by Hetero Labs Limited